Impact of microvasculature invasion subtype (MVI vs. LVI) and associated risk factors on survival outcomes in pancreatic cancer after curative surgery

微血管侵犯亚型(MVI 与 LVI)及其相关危险因素对胰腺癌根治术后生存结局的影响

阅读:1

Abstract

OBJECTIVE: This study aims to investigate the risk factors associated with microvasculature invasion (MI) in patients with pancreatic cancer and evaluate its prognostic significance. METHODS: A retrospective analysis was conducted on the clinical data of 288 pancreatic cancer patients who underwent radical pancreatectomy between June 2012 and June 2024. The collected data included demographic characteristics, pathological findings, and laboratory results. Logistic regression analysis was performed to identify potential factors associated with the occurrence of MI. The Kaplan-Meier method was employed to estimate disease-free survival (DFS) and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were applied to assess the impact of various factors on patient prognosis. RESULTS: Among 288 patients, MI was detected in 93 patients (32.3%). Positive microvasculature biomarkers, positive regional lymph nodes (RNP), poor differentiation grade, and reduced MCV might be independent risk factors for MI. Multivariate Cox regression analysis showed that MI, tumor site, RNP, grade, chemotherapy, chloride (Cl) and thrombin time were independent risk factors for DFS and OS. Among 93 patients with MI, no statistically significant difference in prognosis was observed between the MVI and LVI subtypes. CONCLUSION: Positive microvasculature biomarkers, positive RNP, poor histological grade, and reduced MCV levels might serve as independent risk factors for the development of MI. The presence of MI was independent risk factors for DFS and OS. However, no significant prognostic association was observed between the specific origin of invasion (whether MVI or LVI).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。